Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - raloxifeno - comprimido revestido por película - 60 mg - raloxifeno, cloridrato 60 mg - raloxifene - genérico - duração do tratamento: longa duração

Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - raloxifeno - comprimido revestido por película - 60 mg - raloxifeno, cloridrato 60 mg - raloxifene - genérico - duração do tratamento: longa duração

Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - raloxifeno - comprimido revestido por película - 60 mg - raloxifeno, cloridrato 60 mg - raloxifene - genérico - duração do tratamento: longa duração

Brasilía - portúgalska - ANVISA (Agência Nacional de Vigilância Sanitária)

casa granado laboratÓrios, farmÁcias e drogarias s/a - produtos naturais associados

Portúgal - portúgalska - myHealthbox

bayer ag - concentração para emulsão (ec) com 100 g/l de deltametrina - piretróide

Evrópusambandið - portúgalska - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacinas - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. o uso desta vacina deve ser de acordo com as recomendações oficiais.

Evrópusambandið - portúgalska - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacinas - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

laboratórios basi - indústria farmacêutica, s.a - hidroxicloroquina - comprimido revestido por película - 200 mg - hidroxicloroquina, sulfato 200 mg - hydroxychloroquine - genérico - duração do tratamento: longa duração

Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - fluoxetina - cápsula - 20 mg - fluoxetina, cloridrato 22.357 mg - fluoxetine - genérico - duração do tratamento: longa duração

Portúgal - portúgalska - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - fluoxetina - cápsula - 20 mg - fluoxetina, cloridrato 22.357 mg - fluoxetine - genérico - duração do tratamento: longa duração